

Vicore Pharma to Present at Upcoming Investor Conferences

Stockholm, February 26, 2026 – Vicore Pharma Holding AB (Nasdaq Stockholm: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAAGs), today announced that the company will participate in the following investor conferences:

- **TD Cowen 46th Annual Health Care Conference**

Location: Boston, USA

Format: Presentation and 1×1 meetings

Presentation Date and Time: Wednesday, March 4 at 1:50 PM EST

Webcast: [Link](#)

Participants: Ahmed Mousa, CEO, and Megan Richards, VP of IR and Comms

- **Leerink Partners Global Healthcare Conference 2026**

Location: Miami, USA

Format: Presentation and 1×1 meetings

Presentation Date and Time: Monday, March 9 at 11:20 AM EST

Webcast: [Link](#)

Participants: Ahmed Mousa, CEO, and Megan Richards, VP of IR and Comms

- **2026 Jefferies Biotech on the Beach Summit**

Location: Miami, USA

Format: 1×1 meetings

Date: Tuesday, March 10

Participants: Ahmed Mousa, CEO, and Megan Richards, VP of IR and Comms

- **Sweden Life Science Day 2026**

Location: Gothenburg, Sweden

Format: Presentation

Presentation Date and Time: Wednesday, March 4 at 9:15 AM CET

Participant: Hans Jeppsson, CFO

For more information, please contact:

Megan Richards, VP of IR and Comms, +1 978 269-4372, megan.richards@vicorepharma.com

Hans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.com

About Vicore Pharma

Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in



Press Release
26 February 2026 08:00:00 CET

the global 52-week Phase 2b ASPIRE trial in IPF.

Vicore is publicly listed on the Nasdaq Stockholm exchange with the ticker VICO. www.vicorepharma.com

Attachments

[Vicore Pharma to Present at Upcoming Investor Conferences](#)